meRfi®-GM
Non-Alcoholic Fatty Liver Disease (NAFLD)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in adults and in the pediatric population of the western world. It is characterized by excessive hepatic fat accumulation, associated with insulin resistance, and is defined by the presence of steatosis in more than 5% of hepatocytes or by a proton density fat fraction greater than 5.6% assessed by imaging techniques.
Non-Alcoholic Fatty Liver Disease (NAFLD) is part o…
References (Sources)
- Interactions between gut microbiota and non-alcoholic liver disease (NAFLD): the role of microbiota-derived metabolites
- Natural History of NAFLD
- Non-Alcoholic Fatty Liver Disease and Its Relationship With Cardiovascular Disease and Other Extrahepatic Diseases
- Nonalcoholic fatty liver disease: pathogenesis and disease spectrum
- Probiotics and nonalcoholic fatty liver disease
- Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
- The global NAFLD epidemic